Table 2.
Cancer Agents Included in Each Treatment Category
| Agent Without Anti-VEGF Activity∗ (n = 116) |
Single-Agent Anti-VEGF TKI∗ (n = 222†) |
Combination of Anti-VEGF TKI With Other Agent∗ (n = 9) |
|||
|---|---|---|---|---|---|
| Agent | n | Agent | n | Agent | n |
| Immune checkpoint inhibitors | Pazopanib | 127 | Lenvatinib/everolimus | 5 | |
| Nivolumab | 54 | Sunitinib | 106 | Sunitinib/gemcitabine | 4 |
| Nivolumab/ipilimumab | 4 | Axitinib | 45 | Sorafenib/erlotinib | 1 |
| Atezolizumab | 1 | Sorafenib | 31 | Axitinib/nivolumab | 1 |
| Nivolumab/varlilumab | 1 | Cabozantinib | 21 | Lenvatinib/nivolumab | 1 |
| Pembrolizumab | 1 | Lenvatinib | 2 | ||
| mTOR inhibitors | |||||
| Everolimus | 52 | ||||
| Temsirolimus | 13 | ||||
| Everolimus/CB-839 glutaminase inhibitor | 2 | ||||
| Interleukin-2 | 8 | ||||
| Chemotherapy | |||||
| Capecitabine/gemcitabine | 3 | ||||
| Carboplatin/paclitaxel | 2 | ||||
| Gemcitabine | 2 | ||||
| Capecitabine | 1 | ||||
| Gemcitabine/doxorubicin | 1 | ||||
| Capecitabine/gemcitabine | 1 | ||||
| Vincristine/cyclophosphamide/dacarbazine | 1 | ||||
| CB-839 glutaminase inhibitor | 1 | ||||
| BCR-ABL TKI | |||||
| Imatinib | 1 | ||||
| MET inhibitors | |||||
| Savolitinib | 1 | ||||
Values are n. Sample sizes indicate the number of patients who received each treatment agent or each treatment category.
MET = mesenchymal epithelial transition; mTOR = mammalian target of rapamycin; TKI = tyrosine kinase inhibitor; VEGF = vascular endothelial growth factor.
∗
The total number of patients who received each treatment category is less than the sum of the sample sizes for the corresponding treatment agents because most patients received more than 1 treatment agent over the follow-up period.
†
Of the cohort of 228 patients, 222 received single-agent anti-VEGF TKIs; 6 received combination treatment (anti-VEGF TKI with another agent) but no single-agent anti-VEGF TKIs.